Javascript is not activated in your browser. This website needs javascript activated to work properly.
You are here

Autoimmunity against INS-IGF2 expressed in human pancreatic islets.

  • Norio Kanatsuna
  • Jalal Taneera
  • Fariba Vaziri Sani
  • Nils Wierup
  • Helena Larsson
  • Ahmed Delli
  • Hanna Skärstrand
  • Alexander Balhuizen
  • Hedvig Bennet
  • Donald F Steiner
  • Carina Törn
  • Malin Fex
  • Åke Lernmark
Publishing year: 2013
Language: English
Pages: 29013-29023
Publication/Series: Journal of Biological Chemistry
Volume: 288
Issue: 40
Document type: Journal article
Publisher: ASBMB

Abstract english

Insulin is a major autoantigen in islet autoimmunity and progression to type 1 diabetes. It has been suggested that the insulin B-chain may be critical to insulin autoimmunity in type 1 diabetes. INS-IGF2 consists of the preproinsulin signal peptide, the insulin B-chain and eight amino acids of the C-peptide in addition to 138 amino acids from the IGF2 gene. We aimed to determine 1) expression of INS-IGF2 in human pancreatic islets and 2) autoantibodies in newly diagnosed type 1 diabetes children and controls. INS-IGF2, expressed primarily in beta cells, showed higher levels of expression in islets from normal compared to donors with either type 2 diabetes (p=0.006) or high HbA1c levels (p<0.001). INS-IGF2 autoantibody levels were increased in newly diagnosed type 1 diabetes patients (n=304) compared to healthy controls (n=355; p<0.001). Displacement with cold insulin and INS-IGF2 revealed that more patients than controls had doubly reactive insulin-INS-IGF2 autoantibodies. These data suggest that INS-IGF2, which contains the preproinsulin signal peptide, the B-chain and eight amino acids of the C-peptide may be an autoantigen in type 1 diabetes. INS-IGF2 and insulin may share autoantibody binding sites, thus complicating the notion that insulin is the primary autoantigen in type 1 diabetes.


  • Endocrinology and Diabetes


  • Diabetes and Celiac Unit
  • Neuroendocrine Cell Biology
  • Paediatric Endocrinology
  • ISSN: 1083-351X
E-mail: ake [dot] lernmark [at] med [dot] lu [dot] se

Principal investigator

Diabetes and Celiac Unit

+46 40 39 19 01

+46 70 616 47 79


Jan Waldenströms gata 35, Malmö


Lund University Diabetes Centre, CRC, SUS Malmö, Jan Waldenströms gata 35, House 91:12. SE-214 28 Malmö. Telephone: +46 40 39 10 00